Pooled analysis of the six studies showed that YB-1 overexpression was associated with the worst overall survival (OS) in NSCLC patients (HR = 1.59, 95% CI [1.27, 2.00], P < 0.001, fixed effect). Here, YBX1 is linked to non-small cell lung carcinoma.